Avondale Starts Inverness Medical (IMA) at Market Outperform
More News related to IMA
- To Manage Weight Over the Holidays, Experts From Alere Say Enjoy, Indulge a Little and Don't Diet!
- OraSure Tech (OSUR) Settles Patent Infringement Suit with Inverness (IMA), Inverness Switzerland, and Church & Dwight (CHD)
- OraSure Tech (OSUR) Settles Patent Infringement Suit with Inverness (IMA), Inverness Switzerland, and Church & Dwight (CHD)
- Alere Secures Prestigious NCQA Accreditation for Wellness & Health Promotion
- OraSure Technologies Announces Settlement of Patent Infringement Lawsuit With Inverness and Church & Dwight
More News related to New Coverage
- Maxim Group Initiates Coverage on Golden Green Enterprises (CHOP) with a Buy
- Hilliard Lyons Initiates Coveage on Approach Resources (AREX) with a Buy
- Wells Fargo Transfers Coverage on Intuitive Surgical (ISRG) to a Market Perform; Raises Valuation Range
- Wedbush Initiates Coverage on Coinstar (CSTR) with an Outperform
- Thomas Weisel Starts FARO Tech. (FARO) at Overweight, $24 Price Target
Avondale Partners initiates coverage on Inverness Medical Innovations (NYSE: IMA) with a Market Outperform rating.
The new coverage follows news on Thursday of last week that Inverness will acquire ACON Labs' 'second territory' rapid diagnostics business.
To see all the analyst action on Inverness, visit our Analyst Rating page on the stock.
Inverness Medical Innovations, Inc. engages in the development, manufacture, and marketing of consumer and professional medical diagnostic products, as well as a range of vitamins and nutritional supplements.
Related Categories
New CoverageStocks Mentioned
-0.04Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
